The above research results suggest that patients in the high-risk group may have more immunotherapy possibilities if a strategy to induce APCs in the TME to promote strong innate signaling could indeed help improve the cross-initiation of tumor antigen-specific CD8+ T cells by increasing chemokine production for effector T-cell trafficking. This evidence concerns the gene CD8A and neoplasm.